drugset / Trial / NCT01504477

Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer

NCT01504477

NaSingle-groupOpen-labelTreatment

Summary

Panitumumab plus bortezomib for colon cancer

Timeline

Start
2011-12
Primary completion
2014-02
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Bortezomib Small molecule Intravenous
Subject Panitumumab Monoclonal antibody 6 mg/kg Intravenous

Indications